Comparison
Bromantane vs Testosterone
Side-by-side of Bromantane and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | Bromantane | Testosterone |
|---|---|---|
| Category | nootropic | hormone |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 11 | 192 |
| Typical dose (mg) ↗ | 75 | 150 |
| Dosing frequency | daily, morning | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | oral | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 3 | 24 |
| Peak (hr) | 168 | 72 |
| Molecular weight | 280.21 | 288.42 |
| Molecular formula | C16H20BrN | C19H28O2 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Schedule III controlled substance (US); WADA banned |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in the US | Schedule III |
| Pregnancy | Not recommended | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 87913-26-6 | 58-22-0 |
| PubChem CID | 9576456 | 6013 |
| Wikidata | Q4093816 | Q150726 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
Edge case: Testosterone is contraindicated in pregnancy; Bromantane is the safer pick if that applies.
Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Testosterone?
Bromantane and Testosterone differ in category (nootropic vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Testosterone?
Bromantane half-life is 11 hours; Testosterone half-life is 192 hours.
Can you stack Bromantane with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper